Pharma Stock Gets ToR Nod For New API & Specialty Chemicals Facility In Andhra Pradesh

The small-cap pharmaceutical company Sigachi Industries Ltd. has declared that it has obtained Terms of Reference (ToR) approval for its upcoming API and specialty chemicals manufacturing facility in Orvakal, Andhra Pradesh. The facility will be located in Orvakal, Kurnool District, and will produce bulk drugs, drug intermediates, and specialty chemicals.

The scheduled strategic project spans 25.09 acres at Guttapadu-Orvakal Node, Plot No. A-10. According to Schedule 5(f) of the EIA Notification, 2006, which applies to the synthetic organic chemicals industry, the facility is classified as Category B1.

Mr. Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited stated - "This is a significant milestone in our journey to become a vertically integrated pharmaceutical manufacturing company. The Orvakal project will anchor our next phase of growth in APIs and specialty chemicals, helping us create scalable, sustainable, and compliant operations for global markets."

"At Sigachi, we are strategically positioning ourselves to cater to increasing global demand by building capacity closer to key markets and regulatory jurisdictions. The new facility will not only strengthen our product supply chain but also enable faster commercialization, seamless tech transfers, and enhanced responsiveness to evolving customer requirements," Amit Raj Sinha further added.

In terms of financials, net sales for the quarter ending in March 2025 were Rs 128.20 crore, rising 23.12% from Rs 104.13 crore for the quarter ending in March 2024. Its net profit dropped 11.79% from Rs. 15.04 crore in the March 2024 quarter to Rs. 13.27 crore in the March 2025 quarter. EBITDA improved 30.42% from Rs. 23.57 crore in Q4FY24 to Rs. 30.74 crore in Q4FY25. The Board has also recommended a final dividend of Re. 0.10/- per share for FY25 subject to approval of members at the ensuing Annual General Meeting.

"FY25 has been a year of transformation and growth for Sigachi Industries. We have strengthened our market leadership through strategic capacity expansions, robust financial performance, and a growing global footprint. Our commitment to R&D excellence is reflected in the upcoming API R&D facility in Hyderabad, which will drive innovation and enhance our product pipeline. Together, we are poised to achieve new milestones in FY26 and beyond," commented Mr. Amit Raj Sinha MD & CEO of Sigachi Industries.

Leading the way in the development of active pharmaceutical ingredients (APIs), intermediates, excipients, vitamin-mineral blends, and operations and management (O&M) services is the objective of Sigachi Industries Limited, a major participant in the worldwide pharmaceutical sector. Telangana, Gujarat, and Karnataka are the five multilocational facilities where the corporation manufactures its wide range of products.

On Friday, 13th June, the shares of Sigachi Industries Ltd were trading 1.41% higher on the BSE at Rs 58.25 per share from the previous close during the afternoon trade around 13:41 IST.